Skip to content
PatentBrief
Get alertsTop ↑

Using Blood and Saliva mRNA to Detect Breast Cancer

This patent describes a method using specific messenger RNA (mRNA) levels in blood or saliva to help detect breast cancer or determine its prognosis.

ActiveExpires 2042Owned by MammogenInvented by Patrick Lilley, Martin J. Keiser, III

Original patent title: “Biomarkers for the diagnosis of breast cancer”

Plain-English explanation by SahiLast reviewed · November 5, 2026

This patent describes a method using specific messenger RNA (mRNA) levels in blood or saliva to help detect breast cancer or determine its prognosis. Owned by Mammogen with 53 claims and 1 forward citation, and it is expected to expire in 2042.

Coverage

What does this patent actually cover?

This patent outlines a method for detecting breast cancer or predicting its outcome. It involves measuring the levels of at least one specific type of molecule called messenger RNA (mRNA) in a sample from a person, like blood or saliva. These measured levels are then sent to a computer and compared to a baseline level from a healthy sample. If the mRNA levels are different, it can indicate the presence of breast cancer or help doctors understand how aggressive it might be. The patent lists 26 specific mRNAs that can be used, and suggests using a combination of them to create a 'biomarker fingerprint' for more accurate diagnosis or prognosis. It also mentions using this information to guide treatment decisions and distinguish between different stages of the cancer.

The gap

What does this patent NOT cover?

  • Detecting breast cancer using only imaging techniques like mammograms.
  • Diagnosing breast cancer based on physical examination alone.
  • Using protein levels or DNA mutations as the primary diagnostic markers.
  • Methods that do not involve measuring mRNA expression levels.
  • Detecting cancers other than breast cancer.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 20240117444
StatusActive
FieldBiotech & Medicine
AssigneeMammogen
InventorsPatrick Lilley, Martin J. Keiser, III
Filed2022
Expires2042
Claims53
Times cited1
LitigationNone on record
Value · $144K–$461KModest

What made this novel

The innovation lies in identifying and utilizing a specific panel of 26 mRNA molecules whose expression levels in blood or saliva are significantly altered in the presence of breast cancer, creating a unique 'fingerprint' for diagnosis and prognosis.

Biomarkers for the diagnosis o…(Primary claim)biotechpharmaceuticalmedical devicesdiagnostics

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Mammogen Inc.'s diagnostic tests

02

Blood-based cancer screening technologies

03

Saliva-based diagnostic assays

Why it matters

The bigger picture

Early and accurate detection of breast cancer significantly improves treatment outcomes and patient survival rates. This patent offers a potential non-invasive method, using readily available samples like blood or saliva, to identify the disease or its likely progression. This could lead to earlier intervention and more personalized treatment strategies.

Filed

February 11, 2022

Market context

Who's building on this

Companies in this space

Mammogen Inc., the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is actively developing and commercializing this technology. Other companies in the diagnostics space are also exploring mRNA-based biomarkers for various cancers, though specific adoption of this exact panel would require further market analysis.

Market impact

This patent aims to establish a new standard for non-invasive breast cancer detection and prognosis. If successful, it could shift diagnostic paradigms away from solely relying on imaging and biopsies towards molecular profiling of blood or saliva, potentially improving accessibility and reducing patient discomfort.

Claim 1 — Plain English

What this patent covers

This patent outlines a method for detecting breast cancer or predicting its outcome. It involves measuring the levels of at least one specific type of molecule called messenger RNA (mRNA) in a sample from a person, like blood or saliva. These measured levels are then sent to a computer and compared to a baseline level from a healthy sample. If the mRNA levels are different, it can indicate the presence of breast cancer or help doctors understand how aggressive it might be. The patent lists 26 specific mRNAs that can be used, and suggests using a combination of them to create a 'biomarker fingerprint' for more accurate diagnosis or prognosis. It also mentions using this information to guide treatment decisions and distinguish between different stages of the cancer.

The clever bit

The innovation lies in identifying and utilizing a specific panel of 26 mRNA molecules whose expression levels in blood or saliva are significantly altered in the presence of breast cancer, creating a unique 'fingerprint' for diagnosis and prognosis.

What it does not cover

  • Detecting breast cancer using only imaging techniques like mammograms.
  • Diagnosing breast cancer based on physical examination alone.
  • Using protein levels or DNA mutations as the primary diagnostic markers.
  • Methods that do not involve measuring mRNA expression levels.
  • Detecting cancers other than breast cancer.

Patent timeline

Filing

Application submitted to the patent office

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Moderate

Citation count

6/40

Early citations

Claim breadth

20/20

Very broad protection

Recency

0/20

Older than 20 years

Assignee scale

20/20

Major company or institution

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$144K – $461K

Midpoint $288K · 15.2 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

53 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cited by later patents

1

later patents that build on this invention

View patents →

Cite this patent

Lilley, P., & III, M. J. K. Using Blood and Saliva mRNA to Detect Breast Cancer (U.S. Patent No. 20,240,117,444). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20240117444/biomarkers-for-the-diagnosis-of-breast-cancer

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US20240117444"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →medical devices patents →

Common Questions

Frequently Asked Questions

What does Using Blood and Saliva mRNA to Detect Breast Cancer cover?

This patent describes a method using specific messenger RNA (mRNA) levels in blood or saliva to help detect breast cancer or determine its prognosis.

Who owns patent US 20240117444?

This patent is owned by Mammogen.

When does this patent expire?

This patent is expected to expire on February 11, 2042, when the invention enters the public domain.

What is patent US 20240117444 cited by?

This patent has been cited by 1 later patents that build on its ideas.

What problem does this patent solve?

Early and accurate detection of breast cancer significantly improves treatment outcomes and patient survival rates. This patent offers a potential non-invasive method, using readily available samples like blood or saliva, to identify the disease or its likely progression. This could lead to earlier intervention and more personalized treatment strategies.

What does this patent NOT cover?

Detecting breast cancer using only imaging techniques like mammograms.

Patent monitoring

Get notified when Mammogen files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 5, 2026 · PatentBrief is not a law firm and this is not legal advice.